Evaluation of Serum Levels of Tissue Inhibitor Metalloproteinase-1and Matrix Metalloproteinase-1 in Egyptian Patients with Diabetic Nephropathy-Reference-Cited by-同舟云学术

Evaluation of Serum Levels of Tissue Inhibitor Metalloproteinase-1and Matrix Metalloproteinase-1 in Egyptian Patients with Diabetic Nephropathy

Published:2022-06-30 Issue:2 Volume:15 Page:831-836
ISSN:2456-2610
Container-title:Biomedical and Pharmacology Journal
language:en
Short-container-title:Biomed. Pharmacol. J.

Author:

Zaki Moushira¹^ORCID,A. Hussein Mona Abd Elmotaleb²^ORCID,Tawfeek Hend M.³^ORCID,Ahmed Nadia Mohamed⁴,M Ibrahim Amr M⁴^ORCID,Youness Eman R.⁴^ORCID

Affiliation:

1. 1Biological Anthropology Department, National Research Centre, Giza, Egypt.

2. 2Internal Medicine National Institute of Diabetes and Endocrinology, Cairo, Egypt.

3. 3Internal Medicine Faculty of Medicine, Al-Azhar University- Girls.

4. 4Medical Biochemistry Department, Medical Research Division, National Research Centre, Giza, Egypt.

Abstract

We aimed to evaluate the levels of serum tissue inhibitor metalloproteinase-1 (TIMP-1) and matrix metalloproteinase-1 (MMP-1) in patients with type 2 diabetes (T2D)alone and in diabetic nephropathy(DN) and assess their relation with other clinical features. This study was conducted on 30 patients withT2D, 30 with diabetic nephropathy (DN) and 50 age- corresponded healthy individuals. Serum MMP-1 and TIMP-1 were measured with ELISA in patients and controls. Elevated serum concetrations of TIMP-1 and MMP-1 were recognized in DN group compared to patients with T2D alone as well as controls. Positive correlation was also observed between MMP-1, TIMP-1, FBG and HbA1c in DN group. In multiple linear regression analysis HBLA1c, TG and low HDL were selected as components significantly related to MMP-1 and TIMP-1 in DN patients. in conclusion, serum MMP-1 and TIMP-1were significantly increased in DN. Further, in DM type 2 both markers were not significantly increased than controls. These blood biomarkers are associated with DN and might be salutary in clinical discrimination of DN in patients with type 2 diabetes.

Publisher

Oriental Scientific Publishing Company

Subject

Pharmacology

Reference22 articles.

1. 1. Birkedal-Hansen H, Moore WGI, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993;4(2):197-250.

2. 2. Reynolds JJ. Collagenases and tissue inhibitors of metalloproteinases: a functional balance in tissue degradation. Oral Dis. 1996;2(1):70-76.

3. 3. Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. Jama. 2016;316(6):602-610.

4. 4. Hovind P, Tarnow L, Rossing P, et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. Bmj. 2004;328(7448):1105.

5. 5. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982;28(10):2077-2080.